Recent preclinical studies show that SS18::SSX drives PRAME expression, which has a role in modulating retinoic acid signaling; indeed, combination treatments incorporating all-trans retinoic acid lead to reduced proliferation and induction of cellular senescence in SS models [79]. Here, SS18 is linked to synovial sarcoma.